EVIDENCE CHAPTER 06
Cancer, tissue, immune, endocrine, autonomic, exposure, and function questions—with every causal limit intact.
ADULT LOSS OF FUNCTION · CANCER · NEUROLOGIC · IMMUNE COURSE
A pathogenic loss-of-function ASH1L finding, invasive papillary thyroid carcinoma, and a later multisystem crisis are present in one longitudinal record. Placing them on one timeline does not declare a shared mechanism. It shows the study needed to test whether they connect.
EARLIER DEVELOPMENT AND CAPACITY
Family-reported historyDelayed early milestones were followed by literacy, strong school performance, and social engagement. That earlier function establishes a meaningful personal baseline before the later turning points.
CHILDHOOD NEUROLOGIC TURNING POINT
Family report + clinical recordHer family describes a severe seizure followed by an abrupt, lasting change in cognition and behavior. Later seizures were reported primarily during sleep, with different responses to different medicines.
CANCER PATHOLOGY
Formal pathologyPathology documented invasive classic papillary thyroid carcinoma with angiolymphatic invasion—tumor cells seen in blood or lymphatic vessels—microscopic extension beyond the thyroid, and regional lymph-node spread. Later family-reported nodules remain surveillance questions; they are not presented as confirmed recurrence.
SEVERE LATER MULTISYSTEM EPISODE
Family-reported history + treatment recordHer family reports that during a later crisis, she lost walking, speech, and safe swallowing and required hospitalization. Immunoglobulin was used acutely and later recurrently; her family describes partial improvement in energy, speech, fainting-like events, and function rather than a full return to the earlier baseline.
NEUROMUSCULAR QUESTION
Formal neurophysiologyNerve-conduction testing was normal, while an EMG (electromyography, a test of muscle electrical activity) abnormality raised the possibility of an inflammatory muscle condition. It did not confirm inflammatory myopathy and does not by itself explain the wider course.
WHAT THIS HISTORY ESTABLISHES
This history places a pathogenic germline loss-of-function finding, papillary thyroid cancer, and a complex neurologic and immune-treatment course in one person. That is enough to justify study, but not enough to assign cause.
COMPETING EXPLANATIONS STAY VISIBLE
The later crisis could relate to cancer, treatment, immune or paraneoplastic processes, medication, another neurologic or neuromuscular condition, or more than one process. Current evidence does not choose among them.
THE DECISIVE NEXT STUDY
Then assess ASH1L allele balance—the relative signal from the two gene copies—along with copy number, expression, protein, chromatin state, and tumor–immune architecture. A normal ASH1L state in the tumor would weaken a direct tumor mechanism; an acquired tumor-specific change would define a testable lead. The neurologic and immune course requires its own measurements over time rather than being inferred from the tumor.
THE WHOLE-BODY QUESTIONS
These observations do not declare new ASH1L syndromes. They identify systems, alternate explanations, and measurements that a serious longitudinal study must preserve.
GROWTH · ENDOCRINE · PUBERTY · BONE
The record includes failure to thrive, low growth-factor measures, thyroid or adrenal-axis questions, early puberty, menstrual-linked seizure or state changes, fractures, chronic leg pain, bone-density concerns, and delayed dentition. Timing, medication, nutrition, mobility, and additional findings must stay attached.
CONNECTIVE · MECHANICAL · MUSCLE
Joint laxity or instability, flat feet, alignment and spine differences, gait burden, pain, fatigue, fractures, oral mechanics, slow healing, and translucent or easily bruised skin appear in selected histories. The strongest formal hypermobility diagnoses also include additional findings, so the record does not establish an ASH1L connective-tissue syndrome.
SKIN · MUCOSA · IMMUNITY
One formally tested child had protective-range values for only a subset of pneumococcal serotypes and selective cytokine findings. Another record contains elevations in selected inflammatory and coagulation-related markers while common inflammatory markers were quiet. Allergy, eczema, infections, oral injury, slow healing, and explicit infection counterexamples remain visible.
AUTONOMIC · CARDIAC · TEMPERATURE
The histories include ventricular rhythm treatment, tachycardia during EEG, breath-holding or cyanosis, unusual cold or sweating, breathlessness, dizziness, fainting-like or drop events, and events with reassuring rhythm capture. Not every episode is the same mechanism.
URINARY · PAIN · INTEROCEPTION
Urinary infections or blood and protein concerns, constipation, dental pain, headaches, extreme pain response, reduced warning from heat or spice, and delayed behavior around discomfort all appear in selected histories.
MEDICATION · SEDATION · ANESTHESIA
The record includes paradoxical sedation failure, prolonged sleepiness, post-anesthesia worsening, stimulant-triggered tics that resolved after withdrawal, mixed antiseizure effects, antibiotic-associated dysregulation, and target-specific improvements. Agent, dose, timing, co-medications, outcome, and recovery are often incomplete.
METHODS & TERMS
Methods & Privacy explains the evidence-label definitions, count rules, missing-information framework, and privacy approach used throughout ASH1L.org.
A genetic result tells us where to look. A life course tells us what the gene may actually mean for a person.
— Abbey